Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics Inc. (ACRS)
:ACRS
RESEARCH TOOLSreports
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)800.83K
Market Cap
$247.21M
Enterprise Value-$42.92M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.10
Next Earnings
May 13, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding107,018,740
10 Day Avg. Volume508,980
30 Day Avg. Volume800,825
Standard Deviation0.41
R-Squared0.00444
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.09
Price to Cash Flow (P/CF)1.90
P/FCF Ratio1.90
Enterprise Value/Market Cap-0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.26
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$11.25Price Target Upside402.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Aclaris Therapeutics News
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?
PremiumCompany Announcements
Aclaris Therapeutics Highlights Drug Progress and Financial Strength
---
Bulls Say, Bears Say
Bulls Say
Financial BackingAn $80 million private placement was announced to support the company's newly bolstered pipeline and operational efforts, showing strong investor interest and financial backing.
Pipeline DevelopmentThe company has strengthened its immunology-focused pipeline with two in-licensed biologics, signaling further growth and innovation.
Bears Say
Pipeline RisksThere are clinical, regulatory, and commercial risks associated with Aclaris Therapeutics' pipeline products.
---
Ownership Overview
29.40% Insiders
4.88% Mutual Funds
0.42% Other Institutional Investors
59.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRS FAQ
What was Aclaris Therapeutics Inc.’s price range in the past 12 months?
Aclaris Therapeutics Inc. lowest stock price was $0.95 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics Inc.’s market cap?
Aclaris Therapeutics Inc.’s market cap is $247.21M.
When is Aclaris Therapeutics Inc.’s upcoming earnings report date?
Aclaris Therapeutics Inc.’s upcoming earnings report date is May 13, 2025 which is in 79 days.
How were Aclaris Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Aclaris Therapeutics Inc. overvalued?
According to Wall Street analysts Aclaris Therapeutics Inc.’s price is currently Undervalued.
Does Aclaris Therapeutics Inc. pay dividends?
Aclaris Therapeutics Inc. does not currently pay dividends.
What is Aclaris Therapeutics Inc.’s EPS estimate?
Aclaris Therapeutics Inc.’s EPS estimate is -0.29.
How many shares outstanding does Aclaris Therapeutics Inc. have?
Aclaris Therapeutics Inc. has 107,018,740 shares outstanding.
What happened to Aclaris Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aclaris Therapeutics Inc.?
Currently, no hedge funds are holding shares in ACRS
---
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (402.23% Upside)
$11.25 (402.23% Upside)
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.9%
Last 30 Days ▼ 12.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.66%
12-Months-Change
Fundamentals
Return on Equity
-25.83%
Trailing 12-Months
Asset Growth
-16.47%
Trailing 12-Months
Company Description
Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
ACRS Stock 12 Month Forecast
Average Price Target
$11.25
▲(402.23% Upside)
Technical Analysis
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-32.67%
reiterated a buy rating 2 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -32.67% per trade.
---